Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors on Renal and Cardiovascular Outcomes

Prasad-Reddy L Isaacs D. A clinical review of GLP- receptor agonists: efficacy and safety in diabetes and beyond. Drugs in Context. 2015;4:212283. doi:10.7573/dic.212283

Gerstein HC Colhoun HM Dagenais GR , et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30.

Marso SP Daniels GH Brown-Frandsen K , et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. doi:10.1056/nejmoa1603827

Marso SP Bain SC Consoli A , et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/nej-moa1607141

Pfeffer MA Claggett B Diaz R , et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-2257. doi:10.1056/nej-moa1509225

Holman RR Bethel MA Mentz RJ , et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228-1239. doi:10.1056/nejmoa1612917

Mosenzon O Wiviott SD Cahn A , et al. Effects of dapa-gliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial [published correction appears in Lancet Diabetes Endocrinol. 2019;7(8):e20]. Lancet Diabetes Endocrinol. 2019;7(8):606-617. doi:10.1016/S22138587(19)30180-9

Neal B Perkovic V Mahaffey KW , et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/nejmoa1611925

Perkovic V de Zeeuw D Mahaffey KW , et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691-704. doi:10.1016/S2213-8587(18)30141-4

Wanner C Inzuchi S Lachin J , et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334. doi:10.1056/NEJMoa1515920

Zinman B Wanner C Lachin JM , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/nej-moa1504720

Packer M Butler AJ Filippatos G , et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med.2020;383:1413-1424.

McMurray JJV Solomon SD Inzucchi SE , et al. Dapa-gliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.

Wiviott SD Raz I Bonaca MP , et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/nejmoa1812389

Heerspink HJL Stefansson BV Correa-Rotter R , et al. Dapa-gliflozin in patients with chronic kidney disease. N Engl J Med. 383:1436-1446.

Perkovic V Jardine MJ Neal B , et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 380:2295-2306.

Cannon CP Pratley R Dagogo-Jack S , et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 383:1425-1435.

Anker SD Butler J Filippatos G Ferreira J , et al. Empa-gliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461.

Ferreira JP Zannad F Butler J , et al. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J. 2022;43(31):2984-2993. doi:10.1093/eurheartj/ehac306

Centers for Disease Control and Prevention. National Diabetes Statistics Report. Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020.